Mylan receives regulatory clearance from European Commission for proposed acquisition of Perrigo

Download PDF Copy

Reviewed

Mylan N.V.Jul 29 2015

Mylan N.V. (NASDAQ: MYL) today announced that it received regulatory clearance from the European Commission under the European Union Merger Regulation (EUMR) for its proposed acquisition of Perrigo Company plc (NYSE: PRGO; TASE).

Mylan's Executive Chairman Robert J. Coury commented, "Today marks yet another important milestone in the process of completing our acquisition of Perrigo and serves as further affirmation of the sound industrial logic of this compelling combination. We look forward to continuing on this path and completing the transaction in the coming months."

As previously announced, on April 24, 2015, Mylan issued a Rule 2.5 announcement (amended on April 29, 2015) under the Irish Takeover Rules setting forth its legally-binding commitment to commence an offer directly to the Perrigo shareholders for the entire issued and to be issued share capital of Perrigo. The proposed transaction remains subject to certain conditions and other terms set forth in the formal Rule 2.5 announcement.

Source:

Mylan N.V.

Posted in: Business / Finance

Comments (0)

Download PDF Copy

Suggested Reading

Better technology access reduces healthcare gaps for African Americans

New oral antiretroviral shows potential as long-acting HIV pre-exposure prophylaxis

An HIV outbreak in Maine shows the risk of Trump’s crackdown on homelessness and drug use

AI rollout in NHS hospitals faces major challenges

Healing with Artificial Intelligence highlights the future of patient care

CHAPPER healthcare, AscellaHealth’s global pharmaceutical distributor, assumes presidency of EUROPACCESS, enhancing access to innovative medicines

Duke-NUS sharpens focus on population health and technology-enabled research

Researchers uncover how HIV-1 uses RNA:DNA hybrids to integrate into the genome

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.